Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon, Genospectra to Launch RNA Assays for Gene Silencing Measurement

NEW YORK, July 22 (GenomeWeb News) - Dharmacon of Lafayette, Colo., and Fremont, Calif.-based Genospectra announced today that they will launch a genome-wide line of assays designed to measure RNA changes directly from cell lysates, fresh tissue and archived tissue samples.


Genospectra will develop a line of its QuantiGene assays corresponding to Dharmacon's siGenome siRNA reagents targeting human genes. The assays will provide measurement of gene-silencing experiments using small interfering RNA (siRNA). According to the firms, using the QuantiGene bDNA assays with Dharmacon's Smartpool siRNA products will enable researchers to accurately and efficiently validate RNAi gene knockdown studies, as well as compare and standardize data between experiments and laboratories.


The partners intend to jointly sell and market the assays to the life sciences research market.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.